Published in Gene Therapy Weekly, November 17th, 1997
In these studies, the Epo gene was delivered successfully to skeletal muscle tissue by using an adeno-associated viral (AAV) gene delivery system, or vector. These findings included prolonged expression of the delivered Epo gene for more than six months following just a single injection, stable production of the Epo protein, and effective gene delivery into non-dividing, adult muscle tissue. Taken...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.